NEW YORK (GenomeWeb News) — Shares in Transgenomic were down 6.4 percent, or $.03, at $.44 in mid-afternoon trading after the company said it was “very disappointed” with its sales performance in the third quarter
 
As GenomeWeb News reported this morning, Transgenomic said third-quarter revenues decreased 26 percent as R&D spending rose 15 percent and income turned swung to a loss.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.